WILMINGTON, Del., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in three healthcare investment conferences in February.
Read more:
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group (“Negma”) has by notice to Mendus requested the conversion of convertible bonds that have been issued to Negma in accordance with the financing agreement announced by Mendus through press releases on 26 August and 26 October 2022.
Read the rest here:
Mendus AB: Mendus announces request for conversion of convertible bonds by Negma Group
NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“Intelligent Bio Solutions” or the “Company”), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, today announced a 1-for-20 reverse split of its common stock, effective at 5:00 P.M. Eastern Time today. Beginning on February 10, 2023, the Company’s common stock will continue to trade on The Nasdaq Capital Market (“Nasdaq”) on a split adjusted basis under the trading symbol “INBS”, but will trade under the following new CUSIP number: 36151G402.
Follow this link:
Intelligent Bio Solutions Inc. Announces Reverse Stock Split
WAYNE, Pa., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the Virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 9:20 AM ET.
Read the original:
Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference
SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today announced that management will conduct a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023 at 12:00 PM ET.
See the original post:
Prometheus Biosciences to Present at the SVB Securities Global Biopharma Conference
FLORHAM PARK, N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced regulatory updates for its approved products, VOQUEZNA™ TRIPLE PAK™ and VOQUEZNA DUAL PAK™, approved in the U.S. for the treatment of H. pylori infection, and its pending New Drug Application (NDA) for vonoprazan for the treatment of erosive esophagitis. Phathom has received complete response letters from the U.S. Food and Drug Administration (FDA) relating to its erosive esophagitis NDA and H. pylori post approval supplement, both of which address specifications and controls for a nitrosamine drug substance related impurity, N-nitroso-vonoprazan (NVP), that was detected in the initial commercial launch materials of VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK. These letters formalize FDA’s request, announced by the Company last month, that Phathom provide additional stability data to demonstrate that levels of the impurity previously found in vonoprazan drug product will remain at or below the daily acceptable intake throughout the proposed shelf life of the product. No additional deficiencies were cited by the FDA in either letter.
Continued here:
Phathom Pharmaceuticals Provides Regulatory Updates
Company to focus on Kv7.2/3 channel opener program and development of lead candidate, ETX-123
Visit link:
Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition
Mechelen, Belgium; 9 February 2023, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today presented encouraging data at the European Society for Blood and Marrow Transplantation (EBMT)-European Hematology Association (EHA) 5th European CAR T-cell Meeting in Rotterdam.
Originally posted here:
Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL